CHMP adopts positive opinion for the marketing authorization of Bayer's (BAYN GY) Finerenone for patients with heart failure with left ventricular ejection fraction ≥40%

Bayer's positive opinion from the CHMP could be a significant catalyst for the company's stock, as it moves closer to marketing authorization for Finerenone.

Newsquawk StaffPublished On the live feed at 3 more headlines followed before this page went public
Newsquawk headlinesUTC

US Senator Warren criticises Trump's nomination of Former Fed Governor Warsh as the new Fed Chair; says no Republican should agree to move forward until Trump stops Fed probe

Netherlands government coalition proposes EUR 5.0bln spending increase for defence

CHMP adopts positive opinion for the marketing authorization of Bayer's (BAYN GY) Finerenone for patients with heart failure with left ventricular ejection fraction ≥40%

Top Iranian security official says Iran to list armed forces of EU countries that blacklisted revolutionary guards as 'Terrorist'

US prescriptions for Novo Nordisk's (NOVOB DC) Wegovy pill were 26,109 for week ended Jan 23, IQVIA data shows

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This development is particularly pertinent for investor sentiment towards Bayer, potentially enhancing its competitive stance in the heart failure treatment market. Watch for market reactions in pharmaceuticals and related equities, as this could influence trading dynamics today.

Related headlines

The whole workspace, free to try.

Try it free